Dr. Klausner, a clinical professor at UCLA, shares the details of his work with genotypic testing for ciprofloxacin susceptibility in Neisseria gonorrhoeae.
The study found that routine gyrA genotyping can be implemented in a large health system and that gyrA results can have an impact on the treatment of patients with N. gonorrhoeae. Ceftriaxone use declined with a rise in ciprofloxacin use, and the test of cure was 100 percent.
“The overall concept is that with rapid detection of Neisseria gonorrhoeae, and detection of key antimicrobial resistant genes, we can enable doctors to do targeted treatment, which will reduce antibiotic selection pressure and decrease the emergence of resistance,” Dr. Klausner said.
“New genotypic Neisseria gonorrhoeae diagnostics are here—highly accurate and predictive of susceptibility and treatment outcomes.”
Read the full article.